Windtree Therapeutics Inc (WINT) Stock Up 100% After Q2 2026 Earnings Release

Shares of Windtree Therapeutics Inc (WINT) recorded a notable upward movement today, trading up 100% following the release of the company's financial and operational results for the second quarter of 2026. Market participants tracked the earnings announcement closely as the company updated its quarterly figures.

The earnings release for Q2 2026 did not specify exact consensus estimates for earnings per share or revenue, reporting them as not applicable. Specific underlying operational guidance or executive commentary beyond the standard financial disclosures was not detailed in the report.

During the session, Windtree Therapeutics Inc (WINT) shares moved from an opening price of $0.0001 to a high of $0.0009, touching a low of $0.0001, before resting at the current price of $0.0002 compared to the previous close of $0.0001.

Windtree Therapeutics Inc (WINT) is classified under the biotechnology sector, specifically within the biological products industry under SEC business classifications, focusing on pharmaceutical preparations without diagnostic substances.

In terms of underlying fundamentals, Windtree Therapeutics Inc (WINT) maintains a market capitalization of $0.01 million. Historical SEC filings indicate net losses of $20.3 million for fiscal year 2024 and $39.2 million for fiscal year 2023, alongside total assets of $32.4 million and total liabilities of $29 million for FY2024.

Broader macroeconomic indicators during the session included the Cboe Volatility Index (VIX) at 15.21 and the 10-year to 2-year Treasury yield spread standing at 0.47.

As trading concludes for the day, Windtree Therapeutics Inc (WINT) remains focused on its biotechnology operations as market data continues to reflect ongoing session developments.